Comprehensive Relationships With Industry and Other Entities—AHA/ACC 2017 Update of ST-Elevation Myocardial Infarction and Non–ST-Elevation Myocardial Infarction Measures

<table>
<thead>
<tr>
<th>Committee Member</th>
<th>Employment</th>
<th>Consultant</th>
<th>Speaker</th>
<th>Ownership/Partnership/Principal</th>
<th>Research</th>
<th>Institutional, Organizational, or Other Financial Benefit</th>
<th>Expert Witness</th>
</tr>
</thead>
<tbody>
<tr>
<td>Jneid Hani, Chair</td>
<td>Baylor College of Medicine—Associate Professor of Medicine; Director of Interventional Cardiology Research; The Michael DeBakey VA Medical Center—Director of Interventional Cardiology</td>
<td>None</td>
<td>None</td>
<td>None</td>
<td>None</td>
<td>None</td>
<td>None</td>
</tr>
<tr>
<td>Daneil Addison</td>
<td>Fellow at Massachusetts General Hospital</td>
<td>None</td>
<td>None</td>
<td>None</td>
<td>None</td>
<td>None</td>
<td>None</td>
</tr>
</tbody>
</table>
| Deepak L. Bhatt   | Executive Director of Interventional Cardiovascular Programs, Brigham and Women’s Hospital Heart & Vascular Center; Harvard Medical School—Professor of Medicine | • Duke Clinical Research Institute: Ferring Pharmaceuticals  
• Duke Clinical Research Institute: Novartis  
• Duke Clinical Research Institute: Bristol-Myers Squibb/Pfizer  
• Duke Clinical | None | None | • Amarin†  
• Amgen†  
• Astra Zeneca†  
• BIOFLOW-V (Biotronik)-clinical trial  
• Bristol Myers Squibb†  
• CardioMEMs HF System Post Approval Study (St. Jude Medical clinical trial)  
• Eisai†  
• Ethicon† | None | ACC JACC Associate Editor†  
ACC.org Senior Associate Editor†  
AHA GWTG Chair*  
Belvoir Publications†  
Cardax*  
Clinical Cardiology*  
Duke Clinical Research Institute Data Safety Monitoring Board  
Harvard Clinical Research Institute: | None |
<table>
<thead>
<tr>
<th>Committee Member</th>
<th>Employment</th>
<th>Consultant</th>
<th>Speaker</th>
<th>Ownership/Partnership/Principal</th>
<th>Research</th>
<th>Institutional, Organizational, or Other Financial Benefit</th>
<th>Expert Witness</th>
</tr>
</thead>
</table>
| Gregg Fonarow    | Ahmanson-UCLA Cardiomyopathy Center Division of Cardiology — Director of UCLA's Cardiology Fellowship | Research Institute: Eli Lilly  
• Elsevier Practice Update  
Cardiology†  
• Population Health Research Institute | None | None | • EVOLVE Short DAPT Study (Boston Scientific)  
• Flowco*  
• Forest Laboratories†  
• Ischemix†  
• Medtronic†  
• Merck and Co, Inc*  
• Pfizer†  
• PLxPharma*  
• Roche†  
• Sanofi Aventis†  
• Takeda*  
• The Medicines Company† | Boehringer Ingelheim  
• Harvard Clinical Research Institute: St. Jude Data Safety Monitoring Board  
• HMP Communications (Journal of Invasive Cardiology Editor in Chief) †  
• Journal of Invasive Cardiology†  
• Mayo Clinic Data Safety Monitoring Board  
• Medscape Cardiology*  
• Merck & Co., Inc. Planning Committee for Clinical Study*  
• Novartis  
• Regado Biosciences*  
• Society of Chest Pain Centers Board of Directors†  
• Slack Publications /Cardiology Research Foundation†  
• VA Healthcare System*  
• WebMD† | None |
<table>
<thead>
<tr>
<th>Committee Member</th>
<th>Employment</th>
<th>Consultant</th>
<th>Speaker</th>
<th>Ownership/Partnership/Principal</th>
<th>Research</th>
<th>Institutional, Organizational, or Other Financial Benefit</th>
<th>Expert Witness</th>
</tr>
</thead>
<tbody>
<tr>
<td>Sana Gokak</td>
<td>ACC/AHA</td>
<td>None</td>
<td>None</td>
<td>None</td>
<td>None</td>
<td>None</td>
<td>None</td>
</tr>
<tr>
<td>Kathleen L. Grady</td>
<td>Northwestern University Feinberg School of Medicine — Professor of Surgery and Medicine; and Administrative Director for Heart Failure</td>
<td>None</td>
<td>None</td>
<td>None</td>
<td>• NIA† &lt;br&gt; • NHLBI†</td>
<td>• AHA*</td>
<td>None</td>
</tr>
<tr>
<td>Lee A. Green</td>
<td>University of Michigan — Professor Emeritus</td>
<td>None</td>
<td>None</td>
<td>None</td>
<td>• Alberta Innovates Health Solutions†</td>
<td>None</td>
<td>None</td>
</tr>
<tr>
<td>Paul Heidenreich</td>
<td>Stanford VA Palo Alto Health Care System — Professor of Medicine</td>
<td>None</td>
<td>None</td>
<td>None</td>
<td>None</td>
<td>None</td>
<td>None</td>
</tr>
<tr>
<td>P. Michael Ho</td>
<td>VA Eastern Colorado Health Care System University of Colorado School of Medicine</td>
<td>• Anthem, Inc.† &lt;br&gt; • Janssen Pharmaceuticals, Inc†</td>
<td>None</td>
<td>None</td>
<td>None</td>
<td>None</td>
<td>None</td>
</tr>
<tr>
<td>Committee Member</td>
<td>Employment</td>
<td>Consultant</td>
<td>Speaker</td>
<td>Ownership/Partnership/Principal</td>
<td>Research</td>
<td>Institutional, Organizational, or Other Financial Benefit</td>
<td>Expert Witness</td>
</tr>
<tr>
<td>-------------------</td>
<td>------------</td>
<td>------------</td>
<td>---------</td>
<td>-------------------------------</td>
<td>----------</td>
<td>-----------------------------------------------------</td>
<td>---------------</td>
</tr>
<tr>
<td>Corrine Jurgens</td>
<td>Stony Brook University — Associate Professor</td>
<td>None</td>
<td>None</td>
<td>None</td>
<td>None</td>
<td>None</td>
<td>None</td>
</tr>
<tr>
<td>Marjorie King</td>
<td>Assistant Professor of Medicine at Columbia University Medical Center and Chief Medical Officer at Helen Hayes Helen Hayes Hospital</td>
<td>• Island Peer Review Organization†</td>
<td>None</td>
<td>None</td>
<td>None</td>
<td>None</td>
<td>None</td>
</tr>
<tr>
<td>Dharam Kumbhani</td>
<td>UT Southwestern Medical Center — Assistant Professor of Medicine</td>
<td>• ACC†</td>
<td>None</td>
<td>None</td>
<td>None</td>
<td>None</td>
<td>None</td>
</tr>
<tr>
<td>Samir Pancholy</td>
<td>The Wright Center for Graduate Medical Education</td>
<td>None</td>
<td>• Metronic</td>
<td>• Pfizer†</td>
<td>• Terumo Medical</td>
<td>• Duke Clinical Research Institute Odyssey Outcomes Trial</td>
<td>None</td>
</tr>
</tbody>
</table>

This table represents the relationships of committee members with industry and other entities that were reported by authors to be relevant to this document. These relationships were reviewed and updated in conjunction with all meetings and/or conference calls of the writing committee during the document development process. The table does not necessarily reflect relationships with industry at the time of publication. A person is deemed to have a significant interest in a business if the interest represents ownership of 5% or more of the voting stock or share of the business entity, or ownership of $5,000 or more of the fair market value of the business entity; or if funds received by the person from the business entity exceed 5% of the person’s gross income for the previous year. A relationship is considered to be modest if it is less than significant under the preceding definition. Relationships in this table are modest unless otherwise noted.

*No financial relationship †Significant (greater than $5,000) relationship.
ACC indicates American College of Cardiology; AHA, American Heart Association; BIOFLOW-V, A Prospective Randomized Multicenter Study to Assess the Safety and Effectiveness of the Orsiro Sirolimus Eluting Coronary Stent System in the Treatment Of Subjects With up to Three De Novo or Restenotic Coronary Artery Lesions - V; EVOLVE DAPT, A Prospective, Multicenter, Single-arm Study Designed to Assess the Safety of 3-month Dual Antiplatelet Therapy in Subjects at High Risk for Bleeding Undergoing Percutaneous Coronary Intervention With the SYNERGY Everolimus-Eluting Platinum Chromium Coronary Stent System; GWTG; Get With The Guidelines; HF, heart failure; IMPROVE HF, Improving evidence-based care for heart failure in outpatient cardiology practices; JACC, Journal of the American College of Cardiology; JAMA, Journal of the American Medical Association; NHLBI, National Health, Lung, and Blood Institute; NIA, National Institute on Aging; NIH/NIAID, National Institutes of Health/National Institute of Allergy and Infectious Disease; UCLA, University of California Los Angeles; UT, University of Texas; and VA, Veterans Affairs.